KIT and systemic mastocytosis: Furthermore, in the few patients with proven SM lacking the D816V KIT mutation, sequencing of the whole KIT gene becomes essential for a clear distinction between patients who are candidates for treatment with imatinib (e.g. patients with mutations in exons 8–11) and those who are imatinib-resistant (e.g. patients with other mutations in exon 17).